What Is Setmelanotide Approved For? Label Indications, Per the Research

Setmelanotide is a prescription medicine, and its approved indications are unusually narrow: they are defined by a specific molecular cause of obesity rather than by body weight alone. The published first-approval literature recorded that setmelanotide was approved in the United States in November 2020 for chronic weight management in adult and paediatric patients aged 6 years and older with obesity due to proopiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency confirmed by genetic testing (PMID 33638809). Subsequent reviews described the label being extended to obesity in Bardet-Biedl syndrome (BBS) following a randomised phase 3 trial (PMID 36992862, PMID 36356613). This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any medicine, including setmelanotide, is appropriate in an individual case.

What setmelanotide is, in mechanistic terms

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, and reviews of obesity pharmacotherapy grouped it with agents that act directly on the hypothalamic melanocortin pathway that regulates hunger and energy expenditure (PMID 34783910). The first-approval review explained that the approved indications correspond to genetic defects upstream of MC4R, where the receptor itself remains intact and can be stimulated pharmacologically (PMID 33638809). A 2024 review of severe obesity due to hypothalamic dysfunction described the same pathway logic, noting that disruption of melanocortin signalling in the hypothalamus is the shared feature across the conditions in which the drug has been studied (PMID 39526054). For a broader overview of the molecule and its study history, see the setmelanotide learn page.

Approved indications described in the literature

Labelling is not identical in every jurisdiction, and the wording of an indication, the eligible age range and any genetic-testing requirement are set by each regulator. Published reviews summarise approvals at the time of writing, so the authoritative source for any given country remains the current prescribing information in that country.

The original genetic obesity indications

The Drugs first-approval article recorded that setmelanotide was developed for rare monogenic forms of obesity and was authorised for chronic weight management in obesity attributable to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing (PMID 33638809). The requirement for molecular confirmation is a defining feature of the label: the approval is not for obesity in general, and reviews of obesity pharmacotherapy have consistently placed setmelanotide in a separate category from agents indicated for common obesity (PMID 34783910, PMID 40995421).

The Bardet-Biedl syndrome indication

Bardet-Biedl syndrome is a rare ciliopathy in which obesity is a cardinal feature alongside retinal degeneration, polydactyly, renal anomalies and learning difficulties, as summarised in a 2024 clinical overview (PMID 38383825) and in a 2026 reference chapter on the syndrome (PMID 42475468). The pivotal evidence came from a multicentre, randomised, double-blind, placebo-controlled phase 3 trial with an open-label period that enrolled patients with BBS and with Alström syndrome; researchers reported that setmelanotide produced significant reductions in body-mass index among participants with BBS over the 52-week study period (PMID 36356613). The same trial report described the Alström syndrome cohort as small, and the published results did not support an equivalent efficacy conclusion in that group (PMID 36356613).

A 2025 analysis in the Journal of Clinical Endocrinology and Metabolism examined cardiometabolic outcomes in BBS participants and reported improvements in components of metabolic syndrome risk during setmelanotide treatment (PMID 39919037). The 2024 BBS overview placed the drug within a wider management framework that also includes vision, renal and developmental care, rather than presenting weight management as the sole clinical priority (PMID 38383825).

Age range

The first-approval literature recorded an initial US indication covering adults and children aged 6 years and older (PMID 33638809). A 2025 review of pharmacological management of paediatric obesity discussed setmelanotide among the limited number of medicines available for children with rare genetic obesity syndromes and noted that paediatric labelling in this field has continued to evolve (PMID 38321079). Because minimum-age wording can be revised after a review article is published, the current prescribing information is the only reliable statement of which ages are covered today.

Uses that appear in the literature as studied, not approved

The sections below describe settings in which setmelanotide has been investigated or discussed. None of these should be read as approved indications unless a current label in the relevant country says otherwise.

Acquired hypothalamic obesity

Hypothalamic obesity can follow surgery, radiotherapy or tumour involvement of the hypothalamus, and a 2024 review described the rationale for MC4R agonism in severe obesity due to hypothalamic dysfunction (PMID 39526054). A randomised trial published in the New England Journal of Medicine evaluated setmelanotide in acquired hypothalamic obesity and reported reductions in body-mass index relative to placebo (PMID 42418774). Whether a regulator has incorporated that indication into the label in any particular country is a question of current labelling, and the prescribing information should be checked rather than inferred from trial publications.

Prader-Willi syndrome

A 2023 review of clinical trials in Prader-Willi syndrome catalogued the pharmacological agents studied for hyperphagia and obesity in that condition, including melanocortin-pathway approaches, and described the field as still searching for consistently effective therapy (PMID 36768472). Prader-Willi syndrome is not among the indications recorded in the first-approval literature (PMID 33638809).

Alström syndrome

Alström syndrome participants were enrolled alongside BBS participants in the phase 3 trial, but the published report described that cohort as small and did not establish the same efficacy finding seen in BBS (PMID 36356613).

Common (polygenic) obesity

Reviews of obesity pharmacotherapy from 2023 and 2025 positioned setmelanotide as a targeted therapy for rare melanocortin-pathway disorders and discussed incretin-based and other agents separately for common obesity (PMID 36992862, PMID 40995421). Those reviews did not describe setmelanotide as an approved option for obesity without an identified melanocortin-pathway cause (PMID 40995421).

Adverse Events in the Approved Indications: What Studies Report

The first-approval review summarised the safety profile accumulated during the development programme and listed skin hyperpigmentation, injection-site reactions and nausea among the adverse effects reported with setmelanotide (PMID 33638809). In the phase 3 BBS and Alström syndrome trial, researchers reported that skin hyperpigmentation, injection-site reactions and nausea were among the most frequent adverse events, and the study described the drug as generally tolerated across the 52-week period (PMID 36356613). Hyperpigmentation is an on-target consequence of melanocortin receptor activation and was discussed in that context by a review of drugs for treating obesity (PMID 34783910).

Reviews of obesity pharmacotherapy have also noted that monitoring requirements accompany melanocortin agonist therapy, including attention to skin changes and to psychiatric symptoms, and that specialist oversight is expected in these rare-disease populations (PMID 36992862, PMID 39526054). The 2025 BBS cardiometabolic analysis reported outcomes within the same trial population rather than in a general obesity cohort, which limits how far its findings extend beyond that setting (PMID 39919037). No dosing information appears on this page; the schedule, formulation and any adjustments are matters for the prescribing clinician and the current prescribing information.

Why genetic confirmation matters to the label

The approved indications are built around a mechanism, which is why diagnostic confirmation appears in the labelling language recorded at first approval (PMID 33638809). The 2024 hypothalamic dysfunction review explained that identifying where melanocortin signalling is interrupted determines whether an MC4R agonist has a plausible target at all (PMID 39526054). The 2024 BBS overview and the 2026 syndrome chapter both emphasised that diagnosis in these conditions is often delayed, which has downstream consequences for access to any targeted therapy (PMID 38383825, PMID 42475468).

Reading the evidence carefully

• Approval is population-specific. The recorded indications attach to defined genetic or syndromic diagnoses rather than to obesity as a category (PMID 33638809).
• Trial populations were small. Rare-disease trials enrol limited numbers, and the phase 3 BBS and Alström syndrome study illustrated how cohort size constrains conclusions in the smaller group (PMID 36356613).
• Review articles date quickly. Approval status described in a 2023 or 2025 review reflects that moment in time (PMID 36992862, PMID 40995421).
• Trial publication is not the same as labelling. The acquired hypothalamic obesity trial reported outcomes, which is a separate question from what a regulator has authorised (PMID 42418774).

Questions about eligibility, genetic testing, monitoring and alternatives belong with a prescribing clinician who can review an individual diagnosis against the current label in the relevant country.

References

• Setmelanotide: First Approval (Drugs, 2021)
• Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period (The Lancet Diabetes & Endocrinology, 2022)
• Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome (The Journal of Clinical Endocrinology and Metabolism, 2025)
• Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management (Diabetes, Obesity & Metabolism, 2024)
• Bardet-Biedl Syndrome (2026)
• Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction (TouchREVIEWS in Endocrinology, 2024)
• Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (The New England Journal of Medicine, 2026)
• Clinical Trials in Prader-Willi Syndrome: A Review (International Journal of Molecular Sciences, 2023)
• Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (EClinicalMedicine, 2023)
• Pharmacotherapy for Obesity: Recent Updates (Clinical Pharmacology: Advances and Applications, 2025)
• Current and future state of pharmacological management of pediatric obesity (International Journal of Obesity, 2025)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)